These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

203 related items for PubMed ID: 38553594

  • 1. A prospective phase II clinical trial of total neoadjuvant therapy for locally advanced gastric cancer and gastroesophageal junction adenocarcinoma.
    Shi JM, Li N, Jiang LM, Yang L, Wang SL, Song YW, Liu YP, Fang H, Lu NN, Qi SN, Chen B, Li YX, Zhao DB, Tang Y, Jin J.
    Sci Rep; 2024 Mar 29; 14(1):7522. PubMed ID: 38553594
    [Abstract] [Full Text] [Related]

  • 2. [Neoadjuvant chemoradiotherapy combined with surgery versus direct surgery in the treatment of Siewert type II and III adenocarcinomas of the esophagogastric junction: long-term prognostic analysis of a prospective randomized controlled trial].
    Tian Y, Wang Q, Wang J, Qiao XY, Zhang J, Lin YC, Li Y, Fan LQ, Yang PG, Zhao Q.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb 25; 24(2):128-137. PubMed ID: 33508918
    [Abstract] [Full Text] [Related]

  • 3. Total neoadjuvant therapy for locally advanced gastric cancer and esophagogastric junction adenocarcinoma: study protocol for a prospective, multicenter, single-arm, phase II clinical trial.
    Shi J, Li N, Tang Y, Jiang L, Yang L, Wang S, Song Y, Liu Y, Fang H, Lu N, Qi S, Chen B, Li Z, Liu S, Wang J, Wang W, Zhu S, Yang J, Li Y, Zhao D, Jin J.
    BMC Gastroenterol; 2022 Jul 28; 22(1):359. PubMed ID: 35902798
    [Abstract] [Full Text] [Related]

  • 4. Preoperative Chemoradiotherapy Versus Perioperative Chemotherapy for Patients With Resectable Esophageal or Gastroesophageal Junction Adenocarcinoma.
    Anderegg MCJ, van der Sluis PC, Ruurda JP, Gisbertz SS, Hulshof MCCM, van Vulpen M, Mohammed NH, van Laarhoven HWM, Wiezer MJ, Los M, van Berge Henegouwen MI, van Hillegersberg R.
    Ann Surg Oncol; 2017 Aug 28; 24(8):2282-2290. PubMed ID: 28424936
    [Abstract] [Full Text] [Related]

  • 5. Neoadjuvant chemoradiotherapy improves survival in locally advanced adenocarcinoma of esophagogastric junction compared with neoadjuvant chemotherapy: a propensity score matching analysis.
    Li J, Zhao Q, Ge X, Song Y, Tian Y, Wang S, Liu M, Qiao X.
    BMC Surg; 2021 Mar 17; 21(1):137. PubMed ID: 33731072
    [Abstract] [Full Text] [Related]

  • 6. Fruquintinib plus oxaliplatin combined with S-1 (SOX) as neoadjuvant therapy for locally advanced gastric cancer (GC) or gastro-oesophageal junction adenocarcinoma (GEJ): a multicentre, phase II, single-arm, open-label clinical trial (FRUTINEOGA) protocol.
    Wu L, Yan H, Qin Y, Huang M, Wang T, Jin Q, Wei W.
    BMJ Open; 2024 Feb 10; 14(2):e075696. PubMed ID: 38341203
    [Abstract] [Full Text] [Related]

  • 7. Concurrent Neoadjuvant Chemoradiotherapy for Siewert II and III Adenocarcinoma at Gastroesophageal Junction.
    Zhao Q, Li Y, Wang J, Zhang J, Qiao X, Tan B, Tian Y, Shi G, Xu Q, Li R, Liu Y, Yang P.
    Am J Med Sci; 2015 Jun 10; 349(6):472-6. PubMed ID: 25996101
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of neoadjuvant sintilimab in combination with FLOT chemotherapy in patients with HER2-negative locally advanced gastric or gastroesophageal junction adenocarcinoma: an investigator-initiated, single-arm, open-label, phase II study.
    Li N, Li Z, Fu Q, Zhang B, Zhang J, Wan XB, Lu CM, Wang JB, Deng WY, Ma YJ, Bie LY, Wang MY, Li J, Xia QX, Wei C, Luo SX.
    Int J Surg; 2024 Apr 01; 110(4):2071-2084. PubMed ID: 38320099
    [Abstract] [Full Text] [Related]

  • 9. Two-Year Outcomes and Biomarker Analysis of Locally Advanced Gastric and Gastroesophageal Junction Adenocarcinoma After Neoadjuvant Chemotherapy and Immunotherapy from the Phase II WuhanUHGI001 Trial.
    Sun X, Lyu J, Yang M, Lin Y, Wu K, Liu K, Li A, Shuai X, Cai K, Wang Z, Wang G, Zhang P, Yin Y, Tao K.
    Ann Surg Oncol; 2024 Nov 01; 31(12):8157-8169. PubMed ID: 39154154
    [Abstract] [Full Text] [Related]

  • 10. [Short-term efficacy and safety of the synchronous neoadjuvant chemoradiotherapy with paclitaxel plus carboplatin in stage III adenocarcinoma of esophagogastric junction].
    Ji Y, Peng T, Wang G, Zhang Y, Cao M, Gao Q, Li S.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Sep 25; 21(9):1019-1024. PubMed ID: 30269322
    [Abstract] [Full Text] [Related]

  • 11. Perioperative chemotherapy vs. neoadjuvant chemoradiation in gastroesophageal junction adenocarcinoma : A population-based evaluation of the Munich Cancer Registry.
    Münch S, Habermehl D, Agha A, Belka C, Combs SE, Eckel R, Friess H, Gerbes A, Nüssler NC, Schepp W, Schmid RM, Schmitt W, Schubert-Fritschle G, Weber B, Werner J, Engel J.
    Strahlenther Onkol; 2018 Feb 25; 194(2):125-135. PubMed ID: 29071366
    [Abstract] [Full Text] [Related]

  • 12. A phase II study of neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) chemotherapy followed by surgery and adjuvant S-1 chemotherapy in potentially resectable gastric or gastroesophageal junction adenocarcinoma.
    Park I, Ryu MH, Choi YH, Kang HJ, Yook JH, Park YS, Kim HJ, Jung HY, Lee GH, Kim KC, Kim BS, Kang YK.
    Cancer Chemother Pharmacol; 2013 Oct 25; 72(4):815-23. PubMed ID: 23921575
    [Abstract] [Full Text] [Related]

  • 13. RACE-trial: neoadjuvant radiochemotherapy versus chemotherapy for patients with locally advanced, potentially resectable adenocarcinoma of the gastroesophageal junction - a randomized phase III joint study of the AIO, ARO and DGAV.
    Lorenzen S, Biederstädt A, Ronellenfitsch U, Reißfelder C, Mönig S, Wenz F, Pauligk C, Walker M, Al-Batran SE, Haller B, Hofheinz RD.
    BMC Cancer; 2020 Sep 15; 20(1):886. PubMed ID: 32933498
    [Abstract] [Full Text] [Related]

  • 14. Perioperative chemotherapy versus neoadjuvant chemoradiotherapy for esophageal or GEJ adenocarcinoma: A propensity score-matched analysis comparing toxicity, pathologic outcome, and survival.
    Goense L, van der Sluis PC, van Rossum PSN, van der Horst S, Meijer GJ, Haj Mohammad N, van Vulpen M, Mook S, Ruurda JP, van Hillegersberg R.
    J Surg Oncol; 2017 Jun 15; 115(7):812-820. PubMed ID: 28267212
    [Abstract] [Full Text] [Related]

  • 15. [Safety and efficacy of laparoscopic surgery in locally advanced gastric cancer patients with neoadjuvant chemotherapy combined with immunotherapy].
    Lv JB, Yin YP, Zhang P, Cai M, Chen JH, Li W, Li G, Wang Z, Wang GB, Tao KX.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2023 Jan 25; 26(1):84-92. PubMed ID: 36650004
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: early results of a phase 2 study.
    Jiang H, Yu X, Li N, Kong M, Ma Z, Zhou D, Wang W, Wang H, Wang H, He K, Li Z, Lu Y, Zhang J, Zhao K, Zhang Y, Xu N, Li Z, Liu Y, Wang Y, Wang Y, Teng L.
    J Immunother Cancer; 2022 Mar 25; 10(3):. PubMed ID: 35296556
    [Abstract] [Full Text] [Related]

  • 17. Adjuvant SOX chemotherapy versus concurrent chemoradiotherapy after D2 radical resection of locally advanced esophagogastric junction (EGJ) adenocarcinoma: study protocol for a randomized phase III trial (ARTEG).
    Shen J, Zhu X, Du Y, Zhu Y, Yu P, Yang L, Xu Z, Huang L, Zhang Y, Zhang Y, Liu L, Cheng X.
    Trials; 2021 Oct 30; 22(1):753. PubMed ID: 34717717
    [Abstract] [Full Text] [Related]

  • 18. [Comparison of short-term efficacy and perioperative safety between neoadjuvant therapy and total neoadjuvant therapy in patients with locally advanced rectal cancer].
    Zhai ZW, Zhang KN, Wang C, Han JG, Ma HC, Wei GH, Yang Y, Wang ZJ.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar 25; 23(3):274-280. PubMed ID: 32192307
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predominantly in patients with intestinal type tumors.
    Schulz C, Kullmann F, Kunzmann V, Fuchs M, Geissler M, Vehling-Kaiser U, Stauder H, Wein A, Al-Batran SE, Kubin T, Schäfer C, Stintzing S, Giessen C, Modest DP, Ridwelski K, Heinemann V.
    Int J Cancer; 2015 Aug 01; 137(3):678-85. PubMed ID: 25530271
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.